论文部分内容阅读
加拿大药物管理部门及惠氏制药已发出警戒:坦罗莫司(temsirolimus)(抗肿瘤药)存在较严重的过敏性输液反应的危险。全球已报告了约46例各式各样的ADR,其中6例具有致命危险,已造成1例死亡。在39例该药剂量-时间相关
Canadian drug authorities and Wyeth Pharmaceuticals have warned that temsirolimus (antineoplastic) poses a more serious risk of allergic infusion reactions. About 46 cases of various types of ADR have been reported globally, of which 6 are fatal and one has been fatal. In 39 patients the dose-time-related